Ph3 Study of SOC Chemo + Bevacizumab with or without INCA33890 1L mCC
Phase III Clinical Trial
INCA033890-303: A Randomized Double-Blind Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Participating Locations